



MGC Diagnostics Corporation  
350 Oak Grove Parkway  
Saint Paul, MN 55127  
Telephone: (651) 484-4874  
Facsimile: (651) 484-4826

**FOR IMMEDIATE RELEASE**

## **MGC Diagnostics Corporation Announces Annual Meeting of Shareholders and Fiscal 2016 Year-end Letter to Shareholders**

**SAINT PAUL, MN – March 20, 2017** — MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced details for its upcoming Annual Meeting of Shareholders and its fiscal 2016 year-end letter to shareholders.

### **Annual Meeting of Shareholders**

MGC Diagnostics Corporation's 2017 Annual Meeting of Shareholders will be on Wednesday, March 22, 2017, beginning at 3:30 P.M. CDT. The meeting will be held at MGC's offices located at 350 Oak Grove Parkway, Saint Paul, Minnesota 555127.

### **Year-end Letter to Shareholders**

Please click the link to view our year-end letter to shareholders which can be found in the Business Overview 2016: <http://mgcdiagnostics.com/investor-relations/annual-reports>.

### **About MGC Diagnostics**

MGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and, in the United States, France and Belgium, primarily through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit [www.mgcdiagnostics.com](http://www.mgcdiagnostics.com).

### **Cautionary Statement Regarding Forward Looking Statements**

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2016, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

### **Contacts**

#### Company

Todd M. Austin  
MGC Diagnostics Corporation  
Chief Executive Officer  
(651) 484-4874

#### Investors

Joe Dorame, Robert Blum, Joe Diaz  
Lytham Partners, LLC  
(602) 889-9700  
[mgcd@lythampartners.com](mailto:mgcd@lythampartners.com)

####